Cutaneous CD4+ CD56+ hematologic malignancies

Magro, Cynthia M.; Porcu, Pierluigi; Schaefer, Jochen T.; Erter, Jack W.; Furman, Richard R.; Shitabata, Paul; Crowson, A. Neil

doi:10.1016/j.jaad.2009.08.044

Cited by 27 publications

(23 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 BPDCN affects primarily the elderly and has an aggressive clinical course with a poor prognosis. [5][6][7] Ninety percent of cases presented with asymptomatic solitary/multifocal cutaneous reddish-brown nodules or bruise-like lesions. 5,6 Bone marrow was involved in most cases, however, any organ, can be affected.…”

Section: Discussionmentioning

confidence: 99%

Blastic Plasmacytoid Dendritic Cell Neoplasm

Jabbour

Doumit²,

Maddah³

et al. 2014

kjm

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Blastic Plasmacytoid Dendritic Cell Neoplasm

Jabbour

Doumit²,

Maddah³

et al. 2014

kjm

View full text Add to dashboard Cite

“…It is well established that certain chemotherapy agents can induce maturation of primitive myeloid cells into malignant terminally differentiated myeloid cells. 37 There is limited literature precedent on LCS. In the same vein, primary AML blasts can be induced to differentiate into dendritic-like leukemia cells by culture with certain cytokine combinations.…”

Section: Discussionmentioning

confidence: 99%

Primary Cutaneous Langerhans Cell Sarcoma

Sagransky

Deng

Magro

2013

The American Journal of Dermatopathology

Self Cite

View full text Add to dashboard Cite

Langerhans cell sarcoma (LCS) is a rare but potentially life-threatening neoplastic condition. The diagnosis of LCS requires morphological and immunophenotypic characterization to distinguish it from other epithelioid-appearing malignancies. Four cases of LCS were encountered in the consultative practices of 2 of the authors. The patients ranged in age from 54 to 88 years of age. In 2 of the cases the patients had a history of acute myelogenous leukemia with eruptions occurring after initiation of decitabine. One patient died within 3 months of presenting with the skin eruption, whereas the other patient is in remission. In the other 2 patients, there was no antecedent history; the presentation was in the context of a solitary nodule. One patient declined treatment and died of disseminated metastatic disease. The other patient had complete excision with no evidence of recurrent or metastatic disease. In all cases, the biopsies showed a sheet-like growth of large atypical epithelioid cells. Phenotypic studies revealed positivity for CD4, CD1a, and S100 in all and variable staining for langerin, lysozyme, CD83, CD31, and CD14. Cutaneous LCS represents a terminally differentiated myeloid tumor with a variable but potentially aggressive clinical course. It may be related to a common stem cell defect given the association with acute leukemia. The morphology ranges from atypical appearing Langerhans cell to a high-grade large cell epithelioid malignancy mimicking amelanotic nodular melanoma.

show abstract

“…Typical immunohistochemistry results include positive for CD4, CD56, negative for CD3, CD20, myeloperoxidase, and CD33. This type of lymphoma is highly aggressive and most patients with BPDCN die within a short period of time after diagnosis [4, 8]. Conventional chemotherapy is ineffective.…”

Section: Discussionmentioning

confidence: 99%

Blastic Plasmacytoid Dendritic Cell Neoplasm on the Scalp

2011

View full text Add to dashboard Cite

We describe a 75-year-old Japanese woman with blastic plasmacytoid dendritic cell neoplasm. On her first visit, there were multiple areas of disseminated, elastic hard nodules with multicentric purpura on her scalp. Histopathologically, there were atypical large lymphocytes densely infiltrated through the upper dermis to subcutaneous tissue. Immunohistochemical staining revealed that these infiltrated lymphocytes were CD4, CD56 and vimentin positive. Although we administered several courses of intensive chemotherapy soon after the diagnosis, the patient died 5 months after the first visit.

show abstract

Cutaneous CD4+ CD56+ hematologic malignancies

Cited by 27 publications

References 48 publications

Blastic Plasmacytoid Dendritic Cell Neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm

Primary Cutaneous Langerhans Cell Sarcoma

Blastic Plasmacytoid Dendritic Cell Neoplasm on the Scalp

Contact Info

Product

Resources

About